EverSource Wealth Advisors LLC Has $68,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

EverSource Wealth Advisors LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) by 29.0% during the first quarter, Holdings Channel reports. The institutional investor owned 933 shares of the biopharmaceutical company’s stock after purchasing an additional 210 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $68,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in BMY. Mizuho Securities Co. Ltd. lifted its stake in Bristol-Myers Squibb by 239.0% during the first quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 239 shares during the period. Spectrum Management Group LLC lifted its stake in Bristol-Myers Squibb by 113.1% during the first quarter. Spectrum Management Group LLC now owns 341 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 181 shares during the period. Nauset Wealth Management. LLC bought a new position in Bristol-Myers Squibb during the first quarter worth about $27,000. Conrad Siegel Investment Advisors Inc. bought a new position in Bristol-Myers Squibb during the first quarter worth about $28,000. Finally, Evolution Advisers Inc. bought a new position in Bristol-Myers Squibb during the first quarter worth about $29,000. 76.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BMY shares. BMO Capital Markets raised their price target on shares of Bristol-Myers Squibb from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Monday, September 12th. JPMorgan Chase & Co. lifted their target price on shares of Bristol-Myers Squibb from $80.00 to $85.00 in a research note on Thursday, July 28th. UBS Group lifted their target price on shares of Bristol-Myers Squibb to $73.00 and gave the company an “outperform” rating in a research note on Wednesday, July 27th. Citigroup reiterated a “buy” rating and issued a $90.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, June 3rd. Finally, Berenberg Bank cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and cut their target price for the company from $82.00 to $76.00 in a research note on Wednesday. One analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $76.36.

Insider Activity

In other news, CFO David V. Elkins sold 133,951 shares of the business’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $71.30, for a total value of $9,550,706.30. Following the completion of the transaction, the chief financial officer now owns 100,460 shares of the company’s stock, valued at approximately $7,162,798. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Ann Powell sold 25,000 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $70.75, for a total value of $1,768,750.00. Following the sale, the executive vice president now directly owns 50,476 shares of the company’s stock, valued at approximately $3,571,177. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David V. Elkins sold 133,951 shares of the business’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $71.30, for a total transaction of $9,550,706.30. Following the completion of the sale, the chief financial officer now directly owns 100,460 shares in the company, valued at $7,162,798. The disclosure for this sale can be found here. Insiders sold 208,951 shares of company stock valued at $14,911,456 in the last quarter. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY opened at $71.52 on Friday. The company has a fifty day moving average price of $72.50 and a two-hundred day moving average price of $73.98. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.34 and a current ratio of 1.44. Bristol-Myers Squibb has a 52 week low of $53.22 and a 52 week high of $80.59. The firm has a market capitalization of $152.71 billion, a PE ratio of 23.76, a P/E/G ratio of 1.52 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last released its earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.14. Bristol-Myers Squibb had a net margin of 14.04% and a return on equity of 49.31%. The firm had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.50 billion. During the same quarter in the previous year, the business earned $1.93 EPS. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. As a group, analysts anticipate that Bristol-Myers Squibb will post 7.5 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be issued a $0.54 dividend. This represents a $2.16 annualized dividend and a dividend yield of 3.02%. The ex-dividend date is Thursday, October 6th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 71.76%.

About Bristol-Myers Squibb

(Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.